Could a gentle nerve zap curb explosive outbursts in Prader-Willi syndrome?
NCT ID NCT06144645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests a device that gently stimulates the vagus nerve through the skin (tVNS) to see if it can safely reduce temper outbursts in people with Prader-Willi syndrome. About 102 participants aged 10 to 40 will use either continuous or intermittent stimulation. The study measures safety, how well people tolerate the device, and changes in irritability and outburst frequency.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transcutaneous vagus nerve stimulation (tVNS) device
What this could lead to
If it works, this could provide a non-drug option to reduce temper outbursts in people with Prader-Willi syndrome, improving daily life for them and their families.
What could go wrong
This is a phase 3 trial, but results are not yet available. The device may not reduce outbursts significantly, and some people may find the stimulation uncomfortable or withdraw from the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Mercy Kansas City
Kansas City, Missouri, 64108, United States
-
Christus Children'S
San Antonio, Texas, 78207, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21205, United States
-
Maimonides Medical Center
Brooklyn, New York, 11219, United States
-
Montefiore Medical Center and Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
-
NYU Langone Health
Garden City, New York, 11530, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Rady Children's Hospital San Diego
San Diego, California, 92123, United States
-
Rare Disease Research
Atlanta, Georgia, 30329, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Minnesota
Minneapolis, Minnesota, 55454, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States